Private Advisor Group’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$802K Buy
+8,239
New +$773K ﹤0.01% 1825
2024
Q2
– Sell
-3,465
Closed -$224K – 2431
2024
Q1
$224K Sell
3,465
-81
-2% -$5.27K ﹤0.01% 2039
2023
Q4
$233K Hold
3,546
– – ﹤0.01% 1956
2023
Q3
$202K Buy
3,546
+100
+3% +$6.1K ﹤0.01% 1879
2023
Q2
$211K Hold
3,446
– – ﹤0.01% 1823
2023
Q1
$216K Buy
+3,446
New +$222K ﹤0.01% 1759
2020
Q3
– Sell
-2,098
Closed -$122K – 2876
2020
Q2
$122K Buy
+2,098
New +$114K ﹤0.01% 1594
2014
Q4
– Sell
-916
Closed -$42K – 1188
2014
Q3
$42K Buy
+916
New +$41.3K ﹤0.01% 1066

Other funds holding PBE

Private Advisor Group's PBE Position: Q3 2026 in Review

Private Advisor Group opened a new position in Invesco Biotechnology & Genome ETF (PBE) in Q3 2026: 8,239 shares worth $802K. The stake represents ﹤0.01% of the portfolio and ranks #1825 among its holdings. This is a return to the name: Private Advisor Group previously reported a position in PBE as recently as Q1 2024.

Private Advisor Group first reported a position in PBE in Q3 2014 and has held it in 8 quarters since. 122 funds tracked by Wall St. Rank hold PBE as of Q3 2026.

  • Private Advisor Group held 8,239 shares of Invesco Biotechnology & Genome ETF worth $802K as of Q3 2026.
  • Invesco Biotechnology & Genome ETF was a new Private Advisor Group position in Q3 2026.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of Private Advisor Group's portfolio in Q3 2026, its #1825 holding.
  • Private Advisor Group first reported a position in Invesco Biotechnology & Genome ETF in Q3 2014 and has held it in 8 quarters since.
  • 122 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2026.

Based on Private Advisor Group's 13F filing for Q3 2026, filed 10 Nov 2026.